Skip to main content

Leveraging Gene Therapy to Achieve Long-Term Continuous or Controllable Expression of Biotherapeutics

Published Date

December 13, 2022 - Leading this presentation is guest speaker Dr. Timothy Cripe from Nationwide Children’s Hospital and The Ohio State University. He discusses his latest publication in Science Advances, presents his proof of principle work, and demonstrates that AAV-based delivery of an anti-CD19–anti-CD3 bispecific T cell engager (similar to blinatumomab) can compensate for the otherwise short half-life of the therapeutic, thereby increasing its efficacy against acute lymphoblastic leukemias.